- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07385222
Bækkenbundstræning med eller uden ekstracorporelt magnetisk innervering for for tidlig udløsning
En enkeltcenter, prospektiv interventionsstudie, der sammenligner træning af bækkenbundsmuskler alene versus kombineret med ekstracorporeal magnetisk innervation hos mænd med for tidlig udløsning
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Dette er en single-center, prospektiv interventionsundersøgelse, der prospektivt evaluerede to ikke-farmakologiske tilgange til behandling af for tidlig udløsning (PE): bækkenbundsmuskeltræning (PFMT) alene versus PFMT kombineret med ekstrakorporal magnetisk innervering (ExMI). Voksne mænd med klinisk diagnosticeret PE blev indskrevet på et universitetssygehus' fysioterapi/urologiklinik og fulgt over en 8-ugers interventionsperiode. Forsøget var open-label med parallelle grupper; deltagerne modtog den behandling, der anvendes i klinisk praksis (kun PFMT eller PFMT+ExMI), og resultater blev indsamlet prospektivt i henhold til en foruddefineret protokol.
PE er almindelig og forringer livskvaliteten. PFMT kan forbedre den neuromuskulære kontrol af bækkenbunden, og ExMI leverer stolbaseret magnetisk stimulation for at aktivere bækkenbundsmuskulaturen. Vi formodede, at tilføjelse af ExMI til standard PFMT ville give større forbedringer i bækkenbundsfunktionen og patientrapporterede seksuelle resultater end PFMT alene.
Alle deltagere modtog struktureret undervisning og et progressivt, hjemmebaseret PFMT-program, der blev vejledt i løbet af 8-ugers perioden. PFMT+ExMI-gruppen gennemgik desuden stolbaseret magnetisk stimulation leveret i henhold til klinikkens foruddefinerede protokol, der sigtede mod bækkenbundsmusklerne.
Vurderinger blev udført ved baseline og efter intervention (uge 8), med korttidsopfølgning, hvor det var muligt. Primære resultater var bækkenbundsmuskelforskyvningsafstand og udholdenhed målt med realtid suprapubisk ultralydsscanning under standardiserede instruktioner. Sekundære resultater omfattede Premature Ejaculation Diagnostic Tool (PEDT), International Index of Erectile Function (IIEF-5), Male Sexual Function Inventory-Short Form (MSFI-SF), WHOQOL-BREF seksuel tilfredshedsitem, Global Perceived Effect og sikkerhed/bivirkninger.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Merkez
-
Bolu, Merkez, Tyrkiet (Türkiye), 14030
- Bolu Abant Izzet Baysal University, Faculty of Health Sciences
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- Mand, 25-45 år, seksuelt aktiv
- Klinisk diagnose af for tidlig udløsning stillet af en specialist
- I stand til at følge PFMT og vurderinger
- Komplet baseline kliniske/ultralydsdata
Eksklusionskriterier:
- Neurologisk sygdom (f.eks. multipel sklerose)
- Metaboliske/systemiske/psykiatriske lidelser, der påvirker resultaterne
- Signifikant hjerte-kar-sygdom
- Medicin, der påvirker erektion/udløsning
- Kronisk prostatitis/uretritis eller aktiv urinvejsinfektion
- Peyronies sygdom eller tidligere penisprotese ved baseline
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A - Pelvic Floor Muscle Training (PFMT)
Participants received structured education about pelvic floor anatomy and function and completed an 8-week progressive home-based pelvic floor muscle training program.
The program included both slow and fast pelvic floor muscle contractions performed in five sets daily.
|
Participants performed five sets of pelvic floor muscle exercises daily for 8 weeks.
Each set included slow and fast contractions.
The number of each type of contraction was progressively increased from 10 in week 1, to 20 in week 2, 30 in week 3, and 40 in week 4.
During weeks 5-8, each set included 50 slow and 50 fast contractions.
Correct pelvic floor contraction was taught and verified using real-time ultrasonography.
|
|
Eksperimentel: Arm B - Pelvic Floor Muscle Training (PFMT) + Extracorporeal Magnetic Innervation (ExMI)
Participants completed the same 8-week progressive pelvic floor muscle training program as Arm A and additionally received chair-based extracorporeal magnetic innervation twice weekly for 8 weeks, for a total of 16 sessions.
|
Participants performed five sets of pelvic floor muscle exercises daily for 8 weeks.
Each set included slow and fast contractions.
The number of each type of contraction was progressively increased from 10 in week 1, to 20 in week 2, 30 in week 3, and 40 in week 4.
During weeks 5-8, each set included 50 slow and 50 fast contractions.
Correct pelvic floor contraction was taught and verified using real-time ultrasonography.
Extracorporeal magnetic innervation was delivered using the EMD E-6000 MAGTHER system with the participant seated on the treatment chair.
Treatment was administered twice weekly for 8 weeks, for a total of 16 sessions.
Each session consisted of 10 minutes of intermittent stimulation at 10 Hz, followed by a 1-minute rest period and 10 minutes of intermittent stimulation at 50 Hz.
Stimulation intensity was increased to the highest comfortably tolerated level.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pelvic Floor Muscle Displacement (mm) Assessed by Real-Time Suprapubic Ultrasonography
Tidsramme: Baseline, Week 4, and Week 8
|
Pelvic floor muscle activation was assessed by measuring displacement of the caudal border of the prostate from rest to maximal voluntary pelvic floor contraction using real-time suprapubic ultrasonography.
Three contractions were recorded and averaged.
Greater displacement indicates greater pelvic floor muscle activation.
|
Baseline, Week 4, and Week 8
|
|
Pelvic floor muscle endurance (seconds) on real-time suprapubic ultrasonography
Tidsramme: Baseline, Week 4 and Week 8
|
Pelvic floor muscle endurance was defined as the duration, in seconds, for which the participant could maintain maximal visible pelvic floor elevation during voluntary contraction under real-time suprapubic ultrasonography.
Longer duration indicates greater pelvic floor muscle endurance.
|
Baseline, Week 4 and Week 8
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Premature Ejaculation Diagnostic Tool (PEDT)
Tidsramme: Baseline, Week 4 and Week 8
|
The Premature Ejaculation Diagnostic Tool (PEDT) is a 5-item patient-reported questionnaire assessing ejaculatory control, frequency, minimal stimulation, distress, and interpersonal difficulty related to premature ejaculation.
Total scores range from 0 to 20, with higher scores indicating more severe premature ejaculation symptoms.
|
Baseline, Week 4 and Week 8
|
|
Brief Sexual Function Inventory (BSFI)
Tidsramme: Baseline, Week 4 and Week 8
|
The Brief Sexual Function Inventory (BSFI) assesses male sexual function across domains including sexual drive, erection, ejaculation, problem assessment, and overall satisfaction.
The total score used in this study ranges from 0 to 44, with higher scores indicating better sexual function.
|
Baseline, Week 4 and Week 8
|
|
Five-Item International Index of Erectile Function (IIEF-5)
Tidsramme: Baseline, Week 4 and Week 8
|
The five-item International Index of Erectile Function (IIEF-5) assesses erectile function.
Total scores range from 5 to 25, with higher scores indicating better erectile function.
|
Baseline, Week 4 and Week 8
|
|
World Health Organization Quality of Life-BREF (WHOQOL-BREF) Total Score
Tidsramme: Baseline, Week 4 and Week 8
|
The World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) is a 26-item questionnaire assessing perceived quality of life.
In this study, the raw total score across all 26 items was used.
Possible total scores range from 26 to 130, with higher scores indicating better quality of life.
|
Baseline, Week 4 and Week 8
|
|
Exploratory WHOQOL-BREF Sexual Satisfaction Item
Tidsramme: Baseline, Week 4, and Week 8
|
Sexual satisfaction was assessed using the sexual satisfaction item of the World Health Organization Quality of Life - Brief Version (WHOQOL-BREF).
The item is scored from 1 to 5, with higher scores indicating greater satisfaction with sexual life.
This item was analysed as an exploratory outcome.
|
Baseline, Week 4, and Week 8
|
|
Global Perceived Effect Scale (GPES)
Tidsramme: at Week 8
|
The Global Perceived Effect Scale (GPES) assessed the participant's perceived overall improvement following treatment.
Participants rated their perceived improvement on a scale from 0 to 10, where 0 indicated no improvement and 10 indicated satisfactory/maximal perceived improvement.
Higher scores indicate greater perceived improvement.
|
at Week 8
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Psykiske lidelser
- Kønssygdomme, mandlige
- Mandlige urogenitale sygdomme
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Obstetrisk arbejde, for tidligt
- Obstetriske arbejdskomplikationer
- Graviditetskomplikationer
- Seksuel dysfunktion, Fysiologisk
- Seksuelle dysfunktioner, psykologiske
- Ejakulatorisk dysfunktion
- For tidlig fødsel
- For tidlig ejakulation
Andre undersøgelses-id-numre
- AIBU-FTR-MFU-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .